公开(公告)号：US20240189332A1

公开(公告)日：2024-06-13

申请号：US18224387

申请日：2023-07-20

申请人： Viking Therapeutics, Inc.

发明人： Brian Lian ,  Hiroko Masamune ,  Geoffrey E. Barker

IPC分类号： A61K31/683 ,  A61K31/662 ,  A61K31/665 ,  A61P19/04

CPC分类号： A61K31/683 ,  A61K31/662 ,  A61K31/665 ,  A61P19/04

摘要： The present disclosure is directed to methods of treating fibrotic conditions by administration of TRβ agonists. The disclosure provides methods wherein the abnormal deposition of extracellular matrix components, such as collagen, keratin, or elastin, is reduced, either through interaction of TRβ agonists with TGF-β—dependent inflammatory pathways, or by other mechanisms, thereby ameliorating fibrotic symptoms.

公开(公告)号：US11744873B2

公开(公告)日：2023-09-05

申请号：US17990629

申请日：2022-11-18

申请人： Viking Therapeutics, Inc.

发明人： Brian Lian ,  Geoffrey E. Barker ,  Maureen Barnes ,  Kader Yagiz ,  Erland Stevens

IPC分类号： A61K38/16 ,  A61P43/00

CPC分类号： A61K38/16 ,  A61P43/00

摘要： Disclosed herein are small molecule GIP/GLP-1 dual receptor agonist compositions, pharmaceutical compositions, the use and preparation thereof.

公开(公告)号：US11707472B2

公开(公告)日：2023-07-25

申请号：US16617471

申请日：2018-06-04

申请人： Viking Therapeutics, Inc.

发明人： Brian Lian ,  Hiroko Masamune ,  Geoffrey E. Barker

IPC分类号： A61K31/662 ,  A61K31/665 ,  A61K31/683 ,  A61P19/04

CPC分类号： A61K31/683 ,  A61K31/662 ,  A61K31/665 ,  A61P19/04

摘要： The present disclosure is directed to methods of treating fibrotic conditions by administration of TRβ agonists. The disclosure provides methods wherein the abnormal deposition of extracellular matrix components, such as collagen, keratin, or elastin, is reduced, either through interaction of TRβ agonists with TGF-β-dependent inflammatory pathways, or by other mechanisms, thereby ameliorating fibrotic symptoms.

公开(公告)号：US20240043459A1

公开(公告)日：2024-02-08

申请号：US18486487

申请日：2023-10-13

申请人： Viking Therapeutics, Inc.

发明人： Brian Lian ,  Hiroko Masamune ,  Geoffrey Barker

IPC分类号： C07F9/6574

CPC分类号： C07F9/65742 ,  C07B2200/13

摘要： Disclosed herein are methods of crystallizing the compound of Formula I, as well as crystalline forms thereof. Crystalline forms of Formula I disclosed include the TBME solvate crystalline form, toluene solvate crystalline form, ethanol solvate crystalline form, THF solvate crystalline form, EtOAc solvate crystalline form, acetone solvate crystalline form and crystalline Form C.

公开(公告)号：US11351183B2

公开(公告)日：2022-06-07

申请号：US16095228

申请日：2017-04-24

申请人： Viking Therapeutics, Inc. ,  Metabasis Therapeutics, Inc.

发明人： Brian Lian ,  Rochelle Hanley ,  Misha Dinerman ,  Mark Erion ,  Serge Boyer ,  Hongjian Jiang

IPC分类号： A61K31/662

摘要： Methods useful for treating X-linked adrenoleukodystrophy are provided.

公开(公告)号：US20220016137A1

公开(公告)日：2022-01-20

申请号：US17299998

申请日：2019-12-04

申请人： Viking Therapeutics, Inc.

发明人： Brian Lian ,  Hiroko Masamune ,  Geoffrey E. Barker

IPC分类号： A61K31/662 ,  A61P11/00 ,  A61P29/00 ,  A61P17/02 ,  A61P1/16 ,  A61K31/665

摘要： The present disclosure is directed to methods of treating fibrotic conditions and inflammation by administration of TRβ agonists. The disclosure provides methods wherein the abnormal deposition of extracellular matrix components, such as collagen, keratin, or elastin, is reduced, either through interaction of TRβ agonists with TGF-β-dependent inflammatory pathways, or by other mechanisms, thereby ameliorating fibrotic symptoms.